Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis

Conditions

• Tuberculosis, Pulmonary

Eligibility Criteria

Sex

ALL

Age

21 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• [18F]-FAPI-74 — DRUG
  Each patient will receive approximately 8 mCi of \[18F\]-FAPI-74 intravenously (approximate range for most studies is anticipated to be 6-8 mCi). This will be followed by a vertex to thigh static scan at 30 minutes ( ±5 min) post injection and a low dose CT for attenuation correction. Participants will also undergo high-resolution CT (HRCT) of the chest at baseline and follow-up timepoints, these scans may be done the same day or on different days.

Study Details

This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis. The Investigators propose to use FAP PET/CT to define the extent and location of FAP signals in lungs of TB patients early in TB treatment and after TB cure. These timepoints are chosen as they could be utilized to deliver treatments designed to prevent, predict, or treat Post-transplant Lymphoproliferative Disorder (PTLD). The overarching hypothesis is that greater FAP signals in lungs of adult TB patients are associated with greater imaging manifestations of PTLD after cure.

Key Dates

First listed

Sep 21, 2026

Start date

Sep 30, 2026

Status verified

Sep 2026

Primary completion

Sep 30, 2028

Completion

Sep 30, 2030

Study Design

Enrollment

10 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Pulmonary Tuberculosis Cohort
  Participants aged 21 years of age or older with a diagnosis of pulmonary Tuberculosis

Primary Outcome Measure

Determine the relationship between change in FAP PET signals in lungs during TB treatment and change in lung structural damage in adult patients treated for pulmonary TB. [ Time Frame: 6 months ]

Central Contacts

• Mark A Sellmyer, MD
  (215) 573-3212
  [email protected]
• Erin Schubert
  (215) 573-6569
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA

Related Studies

• 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
  Recruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio